Loading...
Loading...
ARCT| Name | Value |
|---|---|
| Revenues | 32.6M |
| Cost of Revenue | -5.4M |
| Gross Profit | 38.0M |
| Operating Expense | 63.0M |
| Operating I/L | -30.4M |
| Other Income/Expense | -0.1M |
| Interest Income | 4.0M |
| Pretax | -26.4M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -26.8M |
Arcturus Therapeutics Holdings Inc. is an RNA medicines company based in the United States. The company focuses on developing vaccines for infectious, liver, and respiratory rare diseases. Its development programs include LUNAR-OTC for ornithine transcarbamylase deficiency and LUNAR-CF for cystic fibrosis lung disease. Additionally, the company has vaccine programs such as LUNAR-COV19 and LUNAR-FLU. Arcturus Therapeutics has collaboration partnerships with various organizations for the development of nucleic acid-based therapeutic candidates and mRNA therapeutic and vaccine candidates for rare disease targets and various indications.
